chr17-20453023-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BP4_Strong
The NM_001367292.2(LGALS9B):c.621G>A(p.Met207Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: not found (cov: 19)
Exomes 𝑓: 0.000013 ( 1 hom. )
Failed GnomAD Quality Control
Consequence
LGALS9B
NM_001367292.2 missense
NM_001367292.2 missense
Scores
19
Clinical Significance
Conservation
PhyloP100: 0.742
Genes affected
LGALS9B (HGNC:24842): (galectin 9B) This gene was initially thought to represent a pseudogene of galectin 9; however, this transcript has good exon-intron structure and encodes a predicted protein of the same size as and highly similar to galectin 9. This gene is one of two similar loci on chromosome 17p similar to galectin 9 and now thought to be protein-encoding. This gene is the more centromeric gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.055092186).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LGALS9B | NM_001367292.2 | c.621G>A | p.Met207Ile | missense_variant | 7/11 | ENST00000423676.8 | NP_001354221.1 | |
LGALS9B | NM_001042685.3 | c.621G>A | p.Met207Ile | missense_variant | 7/11 | NP_001036150.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LGALS9B | ENST00000423676.8 | c.621G>A | p.Met207Ile | missense_variant | 7/11 | 1 | NM_001367292.2 | ENSP00000388841.3 |
Frequencies
GnomAD3 genomes Cov.: 19
GnomAD3 genomes
Cov.:
19
GnomAD3 exomes AF: 0.0000134 AC: 3AN: 224158Hom.: 0 AF XY: 0.0000248 AC XY: 3AN XY: 120870
GnomAD3 exomes
AF:
AC:
3
AN:
224158
Hom.:
AF XY:
AC XY:
3
AN XY:
120870
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.0000126 AC: 16AN: 1265466Hom.: 1 Cov.: 30 AF XY: 0.0000206 AC XY: 13AN XY: 630866
GnomAD4 exome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
16
AN:
1265466
Hom.:
Cov.:
30
AF XY:
AC XY:
13
AN XY:
630866
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 19
GnomAD4 genome
Cov.:
19
Bravo
AF:
ExAC
AF:
AC:
2
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 15, 2024 | The c.621G>A (p.M207I) alteration is located in exon 7 (coding exon 7) of the LGALS9B gene. This alteration results from a G to A substitution at nucleotide position 621, causing the methionine (M) at amino acid position 207 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N
PrimateAI
Benign
T
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Benign
T;T
Sift4G
Benign
T;T
Polyphen
B;B
Vest4
MutPred
Gain of catalytic residue at S209 (P = 0.152);Gain of catalytic residue at S209 (P = 0.152);
MVP
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at